ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
ProMIS Neurosciences announced a new *peer‑reviewed publication in the journal *Alzheimer’s & Dementia:*
Translational Research & Clinical Interventions* describing data on selective targeting of toxic Aβ oligomers.23
The study compared binding profiles of several amyloid beta antibodies and found that clinical efficacy correlated with strong binding to toxic oligomers, particularly under conditions where non‑toxic monomers were present in excess.23
PMN310, ProMIS’s lead Alzheimer’s antibody, showed high selectivity for toxic Aβ oligomers with minimal binding to monomer and plaque, supporting the hypothesis that oligomer selectivity may drive better clinical outcomes.123
In preclinical Alzheimer’s mouse models, this oligomer selectivity was associated with complete protection of spatial memory, restoring performance to normal wild‑type levels, reinforcing the mechanistic rationale for PMN310.12
The publication highlights that PMN310 demonstrated no detectable binding to amyloid plaque or vascular deposits, a property that may translate into a lower risk of ARIA (amyloid‑related imaging abnormalities) compared with plaque‑binding antibodies.12
The authors and company link reduced plaque and vascular binding to the potential for fewer ARIA‑E and ARIA‑H events, an important safety consideration seen with other anti‑amyloid therapies.123
The data further support ProMIS’s platform approach of designing antibodies that selectively recognize toxic misfolded oligomeric species while sparing normal protein conformations.25
ProMIS is running the Phase 1b PRECISE‑AD trial of PMN310 in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease, incorporating safety, biomarker, and clinical outcome measures.123
The company reports it is on track to complete enrollment in PRECISE‑AD by the end of 2025, with a blinded 6‑month interim analysis planned for Q2 2026 and top‑line data expected in Q4 2026.123
The PRECISE‑AD trial is powered to provide 95% confidence for detection of ARIA, aiming to generate meaningful insight into ARIA incidence as well as effects on biomarkers and cognition for PMN310.2
ProMIS’s CEO, Neil Warma, stated that the publication reinforces the view that toxic Aβ oligomers are hallmark drivers of Alzheimer’s pathology and that PMN310 could offer meaningful improvements in clinical outcomes and quality of life if the mechanistic advantages translate clinically.123
The company positions these results as laying the groundwork for first proof‑of‑concept clinical data for PMN310, potentially differentiating it from existing anti‑amyloid antibodies on both efficacy and safety (ARIA) profiles.12
Sources:
1. https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-announces-new-peer-reviewed-publication-mokbmqeuprve.html
2. https://www.globenewswire.com/news-release/2025/12/10/3203075/0/en/promis-neurosciences-announces-new-peer-reviewed-publication-highlighting-selective-targeting-of-toxic-oligomers-for-potential-clinical-benefit-and-reduced-aria-risk.html
3. https://www.investing.com/news/company-news/promis-reports-promising-data-for-selective-alzheimers-antibody-93CH-4400779